Artivion, Inc. (AORT)
NYSE: AORT · Real-Time Price · USD
24.64
+0.39 (1.61%)
Mar 31, 2025, 3:37 PM EDT - Market open
Artivion Revenue
In the year 2024, Artivion had annual revenue of $388.54M with 9.75% growth. Artivion had revenue of $97.31M in the quarter ending December 31, 2024, with 3.88% growth.
Revenue (ttm)
$388.54M
Revenue Growth
+9.75%
P/S Ratio
2.60
Revenue / Employee
$242,836
Employees
1,600
Market Cap
1.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 388.54M | 34.53M | 9.75% |
| Dec 31, 2023 | 354.00M | 40.22M | 12.82% |
| Dec 31, 2022 | 313.79M | 14.95M | 5.00% |
| Dec 31, 2021 | 298.84M | 45.61M | 18.01% |
| Dec 31, 2020 | 253.23M | -23.00M | -8.32% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
AORT News
- 26 days ago - Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference - PRNewsWire
- 4 weeks ago - Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Artivion Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 6 weeks ago - Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 2 months ago - Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting - PRNewsWire
- 4 months ago - US medical device giant Artivion says hackers stole files during cybersecurity incident - TechCrunch
- 4 months ago - Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis - PRNewsWire
- 5 months ago - Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript - Seeking Alpha